The China Mail - Drew Weissman, Nobel-winning mRNA pioneer

USD -
AED 3.672498
AFN 65.504229
ALL 80.193613
AMD 365.443623
ANG 1.789783
AOA 918.000433
ARS 1490.455074
AUD 1.411542
AWG 1.80125
AZN 1.699459
BAM 1.690479
BBD 2.011669
BDT 122.606854
BGN 1.696366
BHD 0.37668
BIF 2985.954449
BMD 1
BND 1.277583
BOB 11.640953
BRL 5.222395
BSD 0.998833
BTN 95.261679
BWP 13.45607
BYN 3.037988
BYR 19600
BZD 2.008816
CAD 1.387605
CDF 2272.999818
CHF 0.811855
CLF 0.023213
CLP 913.600415
CNY 6.743199
CNH 6.742805
COP 3115.519253
CRC 449.371191
CUC 1
CUP 26.5
CVE 95.306625
CZK 20.924702
DJF 177.864212
DKK 6.462965
DOP 58.464065
DZD 131.663425
EGP 50.234346
ERN 15
ETB 161.573793
EUR 0.86453
FJD 2.234197
FKP 0.739036
GBP 0.738704
GEL 2.610324
GGP 0.739036
GHS 10.937378
GIP 0.739036
GMD 73.500197
GNF 8773.931458
GTQ 7.6209
GYD 208.928649
HKD 7.846982
HNL 26.775574
HRK 6.512302
HTG 130.645231
HUF 313.868996
IDR 17828.1
ILS 2.955101
IMP 0.739036
INR 95.450498
IQD 1308.440296
IRR 1374587.502594
ISK 122.894362
JEP 0.739036
JMD 158.174511
JOD 0.709049
JPY 159.31503
KES 129.09806
KGS 87.449871
KHR 4041.661265
KMF 426.999728
KPW 900.000294
KRW 1416.609785
KWD 0.30868
KYD 0.832361
KZT 463.468603
LAK 22542.892951
LBP 89443.536886
LKR 332.365271
LRD 181.287005
LSL 16.158607
LTL 2.95274
LVL 0.60489
LYD 6.359825
MAD 9.264013
MDL 17.319677
MGA 4300.099399
MKD 53.178616
MMK 2099.791609
MNT 3596.010349
MOP 8.073123
MRU 40.112364
MUR 47.106174
MVR 15.45028
MWK 1731.967674
MXN 17.007555
MYR 4.0859
MZN 63.909745
NAD 16.158607
NGN 1359.570083
NIO 36.760448
NOK 9.4776
NPR 152.41886
NZD 1.69746
OMR 0.381252
PAB 0.998833
PEN 3.368858
PGK 4.486797
PHP 61.464998
PKR 277.41994
PLN 3.724525
PYG 5995.073253
QAR 3.641125
RON 4.526701
RSD 101.421842
RUB 84.020318
RWF 1468.77566
SAR 3.750032
SBD 8.048583
SCR 13.755996
SDG 600.498751
SEK 9.530199
SGD 1.27907
SHP 0.740866
SLE 24.50468
SLL 20969.499227
SOS 570.811185
SRD 37.974495
STD 20697.981008
STN 21.176369
SVC 8.739358
SYP 13001.999906
SZL 16.156273
THB 33.143013
TJS 9.223994
TMT 3.51
TND 2.928476
TOP 2.40776
TRY 47.841255
TTD 6.76693
TWD 32.021601
TZS 2646.873244
UAH 44.681879
UGX 3710.618436
UYU 40.019016
UZS 11890.747223
VES 770.109102
VND 26148.5
VUV 117.940389
WST 2.73449
XAF 566.970915
XAG 0.015456
XAU 0.000229
XCD 2.70255
XCG 1.800078
XDR 0.707052
XOF 566.970915
XPF 103.081378
YER 237.195625
ZAR 16.18059
ZMK 9001.204446
ZMW 18.87722
ZWL 321.999592
  • CMSC

    -0.0250

    21.45

    -0.12%

  • VOD

    0.2000

    16.42

    +1.22%

  • NGG

    -0.1500

    81.05

    -0.19%

  • RIO

    -0.4100

    95.68

    -0.43%

  • RYCEF

    0.1300

    20.84

    +0.62%

  • BCE

    0.1500

    23.47

    +0.64%

  • AZN

    -0.7900

    156.45

    -0.5%

  • RBGPF

    0.0000

    71.34

    0%

  • GSK

    -0.4785

    49.52

    -0.97%

  • BTI

    -0.2900

    57.06

    -0.51%

  • CMSD

    -0.0100

    21.58

    -0.05%

  • BCC

    -0.8900

    83.24

    -1.07%

  • JRI

    0.0635

    12.61

    +0.5%

  • RELX

    -0.2400

    34.43

    -0.7%

  • BP

    0.2196

    42.53

    +0.52%

Drew Weissman, Nobel-winning mRNA pioneer
Drew Weissman, Nobel-winning mRNA pioneer / Photo: © AFP

Drew Weissman, Nobel-winning mRNA pioneer

Drew Weissman's decades of research into mRNA technology paved the way for Covid-19 vaccines, finally earning a Nobel prize for the physician-scientist.

Text size:

The 64-year-old University of Pennsylvania immunologist, who won the Nobel Medicine Prize along with long-time collaborator Katalin Kariko on Monday, is far from done.

His next quests include, among others, developing a vaccine against all future coronaviruses.

"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told AFP recently, referring to the original SARS virus, MERS and Covid-19.

"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now."

- Twin breakthroughs-

The world is now aware of the elegance of the mRNA (messenger ribonucleic acid) vaccines, that deliver genetic instructions to cells telling them to recreate the spike protein of the coronavirus, in order to trigger effective antibodies when they encounter the real thing.

But back when Weissman teamed up with Kariko in the 1990s, the research was considered a scientific dead-end, and working with DNA was considered a more promising avenue.

"We started working together in 1998, and that was without much funding and without much in the way of publications," he said.

In 2005, the pair found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.

"Just before our paper was published, I said 'Our phones are going to ring off the hook,'" he recalls.

"We sat there staring at our phones for five years, and they never rang!"

With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."

Both developments are part of the Pfizer and Moderna Covid-19 vaccines today.

- Helping people -

Weissman grew up in Lexington, Massachusetts.

His father and mother, both since retired, were an engineer and dental hygienist, respectively.

"When I was five years old, I was diagnosed as a type-one diabetic, and back then it was testing urine and taking insulin shots a few times a day," he recalled, and this motivated him to pursue science.

He was educated at Brandeis University and completed an MD-Phd program in immunology at Boston University.

As a young fellow at the National Institutes of Health, he worked for several years in Anthony Fauci's lab on HIV research, before finally arriving at his long-time home Penn.

Weissman was a practicing doctor until a few years ago, and says it brings him great joy that his invention has helped save millions of lives.

"I'm a clinician scientist, my dream since starting college and medical school was to make something that helps people. I think I can say that I've done that. So I am incredibly happy," he said.

Beyond vaccines, mRNA technology is also being heralded for its potential across medicine.

Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.

Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.

Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.

N.Wan--ThChM